Preoperative and Postoperative ctDNA Comparison in Early Stage Lung Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03805256

Enrollment

Registered

2019-01-15

Start date

2018-05-14

Completion date

2019-06-30

Last updated

2019-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preoperative and Postoperative ctDNA Comparison in Early Stage Lung Cnacer

Brief summary

Mutation-positive peripheral blood ctDNA became mutation-negative after surgical removal of the cancer tissue. All subjects in the control group were negative for ctDNA mutations。

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Patients with pulmonary nodules who underwent curative-intent resection were able to enter the study -

Exclusion criteria

Patients who received any invasive examination or treatment prior to resection or had a history of malignancy; patients who do not attend follow up after surgery; blood samples that were contaminated; and biopsies that exhibited advanced lung cancer in pathology。 \-

Design outcomes

Primary

Measure	Time frame	Description
The potential value of ctDNA in the diagnosis of NSCLC	Half a year	The sensitivity,specificity,positive predictive valueand the negative predictive value of mutations in plasma ctDNA for detecting early-stage lung cancer

Countries

China

Contacts

Primary ContactJianping chief physician, Doctor

gongjianpingsz@126.com13701415049

Backup ContactMengqin Xu, Master

xumengqin77@163.com18306202242

Outcome results